Global Pericarditis Market Overview
The Pericarditis Market Size was valued at USD 3.48 Billion in 2023. The Global Pericarditis industry is projected to grow from USD 3.74 Billion in 2024 to USD 6.09 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 5.56% during the forecast period (2024 - 2032).
Pericarditis is inflammation of the pericardium (the fibrous sac surrounding the heart). Symptoms typically include a sudden onset of sharp chest pain. The pain may also be felt in the shoulders, neck, or back. It generally is better sitting up and worse when lying down or breathing deeply.
The increasing prevalence of cardiovascular diseases such as heart attack & hypertension, favorable reimbursement policies, and increasing preference for minimally invasive procedures are the major drivers propelling market growth. However, the side-effects of anti-inflammatory drugs and the risk of bacterial infections constrain the growth of the pericarditis drugs market.
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company with a portfolio of assets that are intended to regulate immunological pathways across a variety of diseases, announced the U.S. in March 2022.
ARCALYST ® (rilonacept) is a recombinant fusion protein that is subcutaneously injected on a weekly basis and is approved by the Food and Drug Administration (FDA) for the treatment of recurrent pericarditis and the reduction of the risk of recurrence in adults and children aged 12 years and older. This protein inhibits the signaling pathways of interleukin-1 alpha (IL-1α) and interleukin-1 beta (IL-1β). Recurrent pericarditis is a painful autoinflammatory cardiovascular disease that primarily manifests as chest pain. It is frequently linked to changes in electrical conduction and, in some cases, the accumulation of fluid around the heart, known as pericardial effusion.
Recurrent pericarditis is diagnosed in patients who experience additional pericarditis episodes after a symptom-free period of 4-6 weeks or longer. Quality of life is impacted by recurrent pericarditis symptoms, which restrict physical activities and result in frequent emergency department visits and hospitalizations. Each year, approximately 40,000 patients in the United States seek and receive treatment for recurrent pericarditis, according to data. Out of that group, approximately 14,000 patients experience a second or subsequent event (recurrence) as a result of persistent underlying disease or an insufficient response to conventional therapies, including nonsteroidal anti-inflammatory medications (NSAIDs), colchicine, and corticosteroids.
Global Pericarditis Market Trends
The prevalence of cardiovascular diseases is found to be increasing over the last decade. This is attributed to the rising incidences of chronic diseases such as obesity and diabetes, which are major risk factors for cardiovascular diseases such as pericarditis, heart attack, and hypertension. As per the American Heart Association, nearly 92.1 million Americans were diagnosed with cardiovascular diseases in 2017. Additionally, it also stated that the prevalence is found to be higher in men than in women. Furthermore, in the same year, more than 92% of the patients exhibited major symptoms of heart diseases such as chest pain, heartburns, and strokes.
Recently, the prevalence of cardiovascular diseases is found to be increasing from the last few years. The American Heart Association stated that in 2015, 3.7% of the Asian population was diagnosed with chronic heart disease, while 21% of the people had hypertension.
Cardiovascular disease is one of the significant chronic disease responsible for a high death toll across the globe. This emphasizes the need for the development of new diagnostics and treatment devices around the world. The market is also affected by the increasing number of people diagnosed with these diseases at an early stage. Therefore, the prevalence of cardiovascular disease would drive the growth of the market during the forecast period.
The pericarditis drugs market is driven by the increasing number of patients suffering from cardiovascular diseases, thus signifying the need for the development of new technologically advanced devices for monitoring the heart rate. Continuous monitoring of cardiovascular diseases is an important aspect of cardiology. Therefore, the prevalence of pericarditis is increasing with a rise in the prevalence of cardiovascular diseases, fueling market growth.
Global Pericarditis Market Segmentation
The global pericarditis market has been segmented into type, application, and end user.
Based on type, the global pericarditis drugs market has been segmented acute pericarditis, recurrent pericarditis, and chronic pericarditis.
Based on diagnosis & treatment, the global market has been divided into diagnosis and treatment. The diagnosis segment is further divided into electrocardiogram (ECG), echocardiogram, computerized tomography (CT), X-Ray. The treatment segment is bifurcated into medication (non-steroidal anti-inflammatory drugs (NSAIDs) and colchicine) and surgical treatment.
Based on end user, the global market has been segmented into hospitals & clinics and medical institutes & research laboratories. The hospitals & clinics segment accounted for a market value of USD 840.30 million in 2017.
Global Pericarditis Market Key Players
The prominent players in the global pericarditis market are:
- Pfizer Inc.
- AstraZeneca Plc
- Novartis International AG
- Allergan plc.
- Merck & Co., Inc.
- Bayer AG
- Reckitt Benckiser Group Plc.
- PerkinElmer, Inc.
- FUJIFILM Holdings Corporation
- Sanofi
- and Johnson & Johnson Services, Inc
Some of the key strategies followed by the players operating in the global pericarditis market are innovation, product development, acquisition, and expansion.
Global Pericarditis Market Regional Analysis
The global pericarditis market, based on region, is segmented into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.
The Americas is estimated to dominate the global pericarditis drugs market during the forecast period. This is attributed to the rising investments in research and development owing to investments in reputed research centers and government institutions and increasing expenditure on healthcare play a vital role in the growth of the regional market. Besides, several research grants are given by governmental agencies.
The European market for pericarditis is expected to be the second-largest during the forecast period. The presence of medical device companies, the rising burden of rheumatoid arthritis (RA), and growing healthcare spending are expected to boost the growth of the market in this region. Additionally, the companies operating in the market are mainly focusing on mergers and acquisition, which is expected to support market growth.
Asia-Pacific is estimated to be the fastest-growing market due to the growing geriatric population, rapid developments in technology. In addition to this, improving healthcare infrastructure has increased the number of research activities in the region. Moreover, in the region, China accounted for a market share of 24.6% in 2017.
Furthermore, the market in the Middle East & Africa is expected to witness slow growth due to limited access to healthcare facilities.
Key Updates
- In July 2017, Pfizer Inc. extended the collaboration with Catalent, Inc., a global provider of advanced delivery technologies and development solutions for drugs, biologics, and consumer health products for the development and manufacture of Advil Liqui-Gels.
- In October 2018, Reckitt Benckiser (RB) launched a 24-hour pain relief patch along with a campaign to educate patients about pain to encourage patients to facilitate pain management.
- In October 2018, FUJIFILM Medical Systems USA, Inc., a provider of diagnostic imaging and medical informatics solutions launched the FCT Embrace wide bore computed tomography (CT) imaging unit in the US, thereby entering into the US computed tomography market.
Market Segmentation
Global Pericarditis Market, by Type
- Acute Pericarditis
- Recurrent Pericarditis
- Chronic Pericarditis
Global Pericarditis Market, by Diagnosis & Treatment
- Diagnosis
- Electrocardiogram (ECG),
- Echocardiogram,
- Computerized Tomography (CT)
- X-Ray
- Treatment
- Medication
- Surgical Treatment
Global Pericarditis Market, by End User
- Hospitals & Clinics
- Medical Institutes & Research laboratories
Global Pericarditis Market, by Region
- Americas
- North America
- Latin America
- Europe
- Western Europe
- Germany
- UK
- France
- Italy
- Spain
- Rest of Western Europe
- Eastern Europe
- Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia-Pacific
Available Additional Customizations
- Pricing Analysis
- Competitive Benchmarking for Global Pericarditis Market
Intended Audience
|
Report Attribute/Metric
|
Details
|
|
Market Size 2032
|
USD 6.09 Billion
|
|
CAGR
|
5.56% (2024-2032)
|
|
Base Year
|
2023
|
|
Forecast Period
|
2024-2032
|
|
Historical Data
|
2020
|
|
Forecast Units
|
Value (USD Billion)
|
|
Report Coverage
|
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
|
|
Segments Covered
|
Type, application, and end user
|
|
Geographies Covered
|
North America, Europe, Asia-Pacific, and Rest of the World (RoW)
|
|
Key Vendors
|
Pfizer Inc., AstraZeneca Plc, Novartis International AG, Allergan plc., and Merck & Co., Inc. are the top five market players in this market. Apart from these, Bayer AG, Reckitt Benckiser Group Plc., PerkinElmer, Inc., FUJIFILM Holdings Corporation, Sanofi, and Johnson & Johnson Services, Inc.
|
|
Key Market Opportunities
|
Development of new diagnostics and treatment devices
|
|
Key Market Drivers
|
Rising preference for minimally invasive diagnostic and treatment procedures and the popularity of robot-assisted cardiac surgeries
|
Pericarditis Market Highlights:
Frequently Asked Questions (FAQ) :
Pericarditis market projected to grow at approximately 5.56% CAGR during the assessment period (2024-2032).
The valuation of the global pericarditis market is estimated to increase to USD 6.09 Billion by the end of 2032.
On the basis of type, acute pericarditis holds majority shares in the global pericarditis market.
Rising preference for minimally invasive diagnostic and treatment procedures and the popularity of robot-assisted cardiac surgeries are major tailwinds pushing the growth of the global pericarditis market.
North America holds the largest share in the global pericarditis market, followed by Europe and the Asia Pacific, respectively.
Sakura Finetek USA, Inc. (U.S.), Hitachi High-Technologies Corporation (Japan), Leica Biosystems Nussloch GmbH (Germany), Euromex Microscopen BV (The Netherlands), ZEISS International (Germany), Celestron LLC (U.S.), Labomed, Inc. (U.S.), Olympus Corporation (Japan), Bruker Corporation (U.S.), and Nikon Corporation (Japan), are some of the top players operating in the global pericarditis market.
